JHOP Articles

Skip to main content

Technology

Acceptance of Artificial Intelligence in Healthcare Is Making Inroads

FDA Updates

Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer

FDA Updates

Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer

FDA Updates

Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML

FDA Updates

Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation

Editorial, Letters to the Editor, Infusion Issues, Adverse Events

JHOP Editorial Board Member, Readers, and Author Interact - Optimizing the Administration of Daratumumab

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Dr Soefje is Director, Pharmacy Cancer Care, Mayo Clinic, Rochester, MN.

Letters to the Editor, Editorial

JHOP Editorial Board Member, Readers, and Author Interact - Comment on Kye et al (April 2023), Authors’ Response

Original Research, Infusion Issues, Adverse Events, Monoclonal Antibodies

Incidence of Infusion-Related Reactions With Pertuzumab and Ado-Trastuzumab Emtansine: A Retrospective Study

Sara Moran Smith, PharmD, BCOP

Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Chemotherapy, Technology

Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist–Based Intravenous Chemotherapy Education and Follow-Up Program

Grant W. Lee, PharmD, BCOP; Joseen J. Chundamala, PharmD; Kerri L. Monahan, PharmD; Judy J. Cho, PharmD; Lydia J. Berry, RPh, PharmD; Christine G. Cambareri, PharmD, BCOP, CSP

Case Reports, PARP Inhibitors, Adverse Events, Oral Therapy, Ovarian Cancer

Successful Extended At-Home Olaparib Desensitization After a Hypersensitivity Reaction: A Case Report

Lily Y. Jia, PharmD, BCOP; Brendan Sendrowski, PharmD, BCOP, DPLA; Timothy Lax, MD; Meghan Shea, MD

Page 34 of 199
Results 331 - 340 of 1986